Trinity Biotech Plc Stock Performance
| TRIB Stock | USD 1.83 0.02 1.10% |
The entity has a beta of 0.59, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Trinity Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Trinity Biotech is expected to be smaller as well. Trinity Biotech plc has an expected return of -0.16%. Please make sure to validate Trinity Biotech value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if Trinity Biotech plc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Trinity Biotech plc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest conflicting performance, the Stock's forward indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Last Split Factor 1:5 | Dividend Date 2015-07-01 | Ex Dividend Date 2015-06-05 | Last Split Date 2024-02-23 |
1 | Mars Water Mystery Deepens With Latest Groundwater Findings | 03/06/2024 |
2 | Krogers Home Chef launches food waste program | 04/03/2024 |
3 | Parafin Secures 125 Million Warehouse Facility from Silicon Valley Bank and Trinity Capital Inc. | 04/09/2024 |
4 | Britains best cities according to science | 04/16/2024 |
5 | White Fox Tattoo Studios Introduces Laser Tattoo Removal, Redefining the Art of Ink Transformation in Indiana | 04/18/2024 |
6 | Dean of top liberal arts university says AI could make Gen Z less skilled, not more You literally dont need to know anything to use the technology | 04/19/2024 |
7 | Aboriginal spears returned to Australia after 250 years in momentous occasion | 04/23/2024 |
8 | California map reveals areas with most high school dropouts | 04/24/2024 |
9 | Tates Creek baseball hoping late-inning rally against Dunbar signals change of fortune | 04/25/2024 |
| Begin Period Cash Flow | 6.6 M |
Trinity |
Trinity Biotech Relative Risk vs. Return Landscape
If you would invest 220.00 in Trinity Biotech plc on January 29, 2024 and sell it today you would lose (37.00) from holding Trinity Biotech plc or give up 16.82% of portfolio value over 90 days. Trinity Biotech plc is currently does not generate positive expected returns and assumes 5.534% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than Trinity, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Trinity Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Trinity Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Trinity Biotech plc, and traders can use it to determine the average amount a Trinity Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.028
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TRIB |
Estimated Market Risk
| 5.53 actual daily | 48 52% of assets are more volatile |
Expected Return
| -0.16 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Trinity Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Trinity Biotech by adding Trinity Biotech to a well-diversified portfolio.
Trinity Biotech Fundamentals Growth
Trinity Stock prices reflect investors' perceptions of the future prospects and financial health of Trinity Biotech, and Trinity Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Trinity Stock performance.
| Return On Equity | -19.13 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.42) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 331.73 M | ||||
| Shares Outstanding | 7.64 M | ||||
| Price To Earning | 31.00 X | ||||
| Price To Book | 5.11 X | ||||
| Price To Sales | 0.25 X | ||||
| Revenue | 56.83 M | ||||
| Gross Profit | 38.08 M | ||||
| EBITDA | (14.3 M) | ||||
| Net Income | (36.87 M) | ||||
| Cash And Equivalents | 10.01 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 54.86 M | ||||
| Current Ratio | 3.66 X | ||||
| Book Value Per Share | (3.12) X | ||||
| Cash Flow From Operations | (19.18 M) | ||||
| Earnings Per Share | (4.96) X | ||||
| Market Capitalization | 13.98 M | ||||
| Total Asset | 59.44 M | ||||
| Retained Earnings | (48.64 M) | ||||
| Working Capital | 29.33 M | ||||
| Current Asset | 151 M | ||||
| Current Liabilities | 21 M | ||||
About Trinity Biotech Performance
To evaluate Trinity Biotech plc Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Trinity Biotech generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Trinity Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Trinity Biotech plc market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Trinity's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 189.82 | 164.45 | |
| Return On Tangible Assets | (0.56) | (0.53) | |
| Return On Capital Employed | (0.36) | (0.34) | |
| Return On Assets | (0.40) | (0.38) | |
| Return On Equity | 1.00 | 1.05 |
Things to note about Trinity Biotech plc performance evaluation
Checking the ongoing alerts about Trinity Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Trinity Biotech plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Trinity Biotech plc generated a negative expected return over the last 90 days | |
| Trinity Biotech plc has high historical volatility and very poor performance | |
| Trinity Biotech plc may become a speculative penny stock | |
| Trinity Biotech plc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 56.83 M. Net Loss for the year was (36.87 M) with profit before overhead, payroll, taxes, and interest of 38.08 M. | |
| Trinity Biotech plc currently holds about 10.01 M in cash with (19.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Roughly 29.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from aol.com: Tates Creek baseball hoping late-inning rally against Dunbar signals change of fortune |
- Analyzing Trinity Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Trinity Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Trinity Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Trinity Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Trinity Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Trinity Biotech's stock. These opinions can provide insight into Trinity Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trinity Biotech plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Trinity Stock analysis
When running Trinity Biotech's price analysis, check to measure Trinity Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Biotech is operating at the current time. Most of Trinity Biotech's value examination focuses on studying past and present price action to predict the probability of Trinity Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trinity Biotech's price. Additionally, you may evaluate how the addition of Trinity Biotech to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Trinity Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (4.96) | Revenue Per Share 7.424 | Quarterly Revenue Growth (0.26) | Return On Assets (0.13) |
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.